combination

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The…

2 weeks ago

Terra Quantum and Axiom Intelligence Acquisition Corp 1 Announce Definitive Business Combination Agreement at a $3.5 Billion Equity Valuation

Combined Company Expected to Trade on Nasdaq Under Ticker Symbol "TQ"Transaction Positions Terra Quantum to Accelerate Global Expansion and Further Strengthen…

2 weeks ago

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

May 15, 2026 20:19 ET  | Source: Regeneron Pharmaceuticals, Inc. The trial did not reach statistical significance for the primary…

3 weeks ago

Ace Green Recycling, Inc. and Athena Technology Acquisition Corp. II Announce $32 Million PIPE Investment to Support Proposed Business Combination

Investment led by seasoned sector-focused institutional investors supports development of Ace's Texas facility and international operationsHOUSTON, April 24, 2026 /PRNewswire/…

2 months ago

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…

2 months ago

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a…

2 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

February 23, 2026 17:10 ET  | Source: Kyntra Bio FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen…

4 months ago

Waters Completes Combination with BD’s Biosciences & Diagnostic Solutions Businesses

Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused…

4 months ago

Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale

DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered…

5 months ago